EGFR and lung cancer: By performing in vitro assays on mutated (H1650 and PC-9) and wild-type (H1299) EGFR lung cancer cell lines, they showed that EGFR promoter hypermethylation enhanced the antitumor effect of TKI gefitinib and modulated the expression of EGFR both at transcript and protein level.